Aclaris Therapeutics, Inc.
ACRS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.75
KIRA · Stoqly’s AI analyst, in plain words
- Aclaris Therapeutics, Inc. had $7.8M of revenue in fiscal 2025, down 58.2% on the year before. Over five years, revenue changed +3.8% a year on average.
- Its operating margin was −975.9%, down 217.7 pts: of every 100 in sales, about −976 is left after running the business.
- Aclaris Therapeutics, Inc. lost $64.9M in fiscal 2025.
- Free cash flow was −$47.2M in fiscal 2025, −603.4% of revenue.
Market cap
$535M
P/E
—
Revenue
$7.8M
Net income
−$64.9M
Free cash flow
−$47.2M
Operating margin
−975.9%
Aclaris Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−58.2%
No. Sales fell 58.2% last year.
Does it make a profit?
−829.6%
No. It lost money last year.
Does profit turn into cash?
−603.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Aclaris Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Aclaris Therapeutics, Inc.
- CIK
- 0001557746
Aclaris Therapeutics, Inc. · ACRS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M |
| Revenue growth | 4.3% | 340.1% | 5.0% | −40.1% | −58.2% |
| Gross margin | 30.3% | 86.5% | 89.0% | 85.1% | 73.3% |
| Operating margin | −1,327.1% | −302.0% | −311.6% | −758.2% | −975.9% |
| Net income | −$90.9M | −$86.9M | −$88.5M | −$132M | −$64.9M |
| Net margin | −1,344.0% | −292.1% | −283.1% | −705.5% | −829.6% |
| Diluted EPS | −$1.60 | −$1.33 | −$1.27 | −$1.71 | −$0.53 |
| Cash | |||||
| Cash from operations | −$52.1M | −$67.6M | −$78.3M | −$20.1M | −$47.1M |
| Capital expenditure | $0.3M | $0.6M | $1.3M | $0.1M | $0.1M |
| Free cash flow | −$52.4M | −$68.2M | −$79.6M | −$20.2M | −$47.2M |
| FCF margin | −775.7% | −229.1% | −254.8% | −107.9% | −603.4% |
| Share count change | 33.4% | 15.0% | 7.0% | 10.7% | 58.6% |
| Debt and strength | |||||
| Cash and short-term investments | $191M | $218M | $119M | $114M | $90.8M |
| Shareholders' equity | $197M | $198M | $157M | $156M | $103M |
| Current ratio | 8.9x | 10.6x | 4.2x | 4.0x | 3.4x |
| Returns and quality | |||||
| Return on equity | −77.3% | −44.0% | −49.9% | −84.5% | −50.2% |
| Return on tangible equity | −47.8% | −45.6% | −56.4% | −84.9% | −63.0% |
| Piotroski F-score | 4 | 5 | 3 | 1 | 2 |
| Altman Z'' | −1.5 | −2.1 | −8.7 | −12.4 | −18.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.4M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aclaris Therapeutics, Inc. · ACRS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.75 a share, the company is worth $535M.
Source: SEC EDGAR XBRL filings (CIK 0001557746). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.